عنوان

بررسی تأثیر ریواستیگمین به عنوان درمان کمکی در بهبود علائم مثبت، منفی و شناختی در بیماران مبتلا به اسکیزوفرنیا، یک کارآزمایی بالینی تصادفی دو سوکور

positive, negative and cognitive symptoms in patients with schizophrenia in a double blind clinical trial. Method In this randomized double blind placebo control clinical trial, 46 male schizophrenia patient (according to DSM-IV-TR criteria) admitted in rehabilitation wards of Razi Psychiatric hospital met the inclusion criteria, considering the antipsychotic they were taking and in order to have a homogenized sample they were chosen randomly and divided to two groups. For one group we used capsules containing rivastigmine and for the other group we used placebo capsules with the same appearance. Positive, negative and general symptoms assessed by PANSS scale, cognitive capacity by MMSE and drug adverse effects assessed by ESRS at several times in the study including admission into the study and in the end of 6 & 12 weeks. For analysis of the data we used repeated measures tests, t test, Mann-Whitney U test, Spearman and Pearson's Correlation Coefficient using SPSS-21 software. Results Adjunctive treatment using rivastigmine showed a significant improvement in cognitive capacity (MMSE) (P<0.01) in 12 weeks starting week 6, whilst there were no meaningful changes in positive (P>0.05), negative (P>0.05) symptoms and general psychopathology (P>0.05). Conclusion Adjunctive treatment with rivastigmine has a meaningful effect on improvement of cognitive capacity at 12 weeks in schizophrenic patientsbut no effect on reduction of positive, negative and general psychopathology is seen. Furthermore the patients age and duration of disease were effective in rivastigmine effect on schizophrenic patiens but familial history has no effect. Key words Rivastigmine, Schizophrenia, cognition, negative symptoms, positive symptoms, general psychopathology

ba